Designer antiandrogens join the race against drug resistance
Jatinder S Josan, John A Katzenellenbogen
eLife · 2013
doi:10.7554/elife.00692 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
By using in silico models of the complexes formed by analogues of a cancer drug and its receptor, it may be possible to strategically redesign existing drugs and win the race against mutations that lead to drug resistance in prostate cancer.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.